Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies

A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment

This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes.

All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice.

The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.

The results will be analyzed based on whether or not participants have a mutation in the Enhancer of zeste homolog 2 (EZH2) gene (known as EZH2 wild-type).

Inclusion Criteria:

• Adults aged 18 years or older
• Histologically confirmed follicular lymphoma grades 1, 2, or 3A
• At least two prior lines of systemic therapy
• Prescribed tazemetostat according to United States prescribing information (USPI)
• Known or planned EZH2 mutation status
• Signed informed consent

Exclusion Criteria:

• Grade 3B or transformed follicular lymphoma
• Other hematologic malignancies
• Use of strong/moderate Cytochrome P450 (CYP3A) inhibitors
• Pregnant or breastfeeding
• Participation in another investigational program